President Barack Obama’s $3.8 trillion budget request for fiscal 2014 attempts to bridge the gap between the competing House and Senate plans adopted last month, particularly on deficit reduction. BGOV Director of Legislative Affairs Loren Duggan and Senior Budget Analyst Cameron Leuthy walk us through the nuts and bolts of the plan.
The Federal Trade Commission reported that there were 40 patent-litigation settlements during fiscal year 2012 that may have involved cash payments from larger brand-name drugmakers to would-be generic competitors. That’s nearly a three-fold increase since 2008. The FTC contends that these deals hurt consumers because they delay the introduction of cheaper generic drugs. Bloomberg Government Analyst Brian Rye explains the current Supreme Court action as the “generic” vs. “brand” fight continues to be an issue.
Allen Scott (moderator) specializes in customer on boarding and training at Bloomberg Government. Allen previously worked at Arbitron, Inc. where he served in a variety of roles from customer service to sales operations manager. Prior to Arbitron, Allen worked in radio for several years in the Washington and Baltimore areas. Most recently he spent six years at 99.1 HFS as co-host and news director.
Loren Duggan is Bloomberg Government’s chief legislative analyst. Before joining Bloomberg, he was editor of Congressional Quarterly’s House Action Reports, providing summaries and analysis of legislation. He also contributed to CQ’s legislative tracking services during his decade with the company. Loren holds a bachelor’s degree in political science and psychology from American University.
Cameron Leuthy is a budget and congressional analyst for Bloomberg Government. Cameron has worked at the White House Office of Management and Budget, the Defense Department, and in the private sector at Booz Allen Hamilton. His expertise includes the budget process and the nexus of national security policy, operational requirements and funding. He has a bachelor’s degree from Western Washington University and an MPA from the University of Washington.
Brian Rye is a health care financial analyst with Bloomberg Government. Before joining Bloomberg, he spent 12 years as an equity research analyst at SunTrust, Raymond James and Janney Montgomery Scott. In those capacities, he followed biotech, pharmaceutical and other health care companies. Rye also served as a senior business management analyst for Booz Allen Hamilton’s civil health group. He received a bachelor’s degree in economics from Vanderbilt University and holds the Chartered Financial Analyst designation.